The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

 INDYMAC BANCORP INC  (IDMC) Trade Now »     Rate IDMC  -  Discuss IDMC  -  Add to Watch List         Graphic_subscribe

  
This is a micro-cap stock and may be a target of manipulation. Always do your research!

SocialPicks Sentiment:

** v.s. other stocks 		This Quarter's Sentiment:
All:
27.5%
Top:
0.0%
Rate IDMC:


Home
Analysis & Videos
Quotes
Bull or Bear
Discuss
        

IDMC: Bull or Bear? From:    SocialPicks  |  Blogsphere  |  All

From the Blogosphere

Cell Genesys, Inc. (CEGE) Halts Cancer Treatment Trial to Ensure Patient Safety
Logo1
38%

Cell Genesys, Inc. (Nasdaq: CEGE) focuses on the development and commercialization of biological therapies to treat multiple types of cancer. The company’s lead product platform, GVAX immunotherapy, holds the potential to treat various types of cancer, including prostate cancer, leukemia, pancreatic cancer and lung cancer. Cell Genesys today announced it has terminated VITAL-2, the second of two phase III clinical trials of GVAX.

<>The trial was set to compare GVAX immunotherapy in combination with Taxotere to Taxotere combined with prednisone in patients with advanced-stage prostate c...
By  StraightStocks   (-6.57%  risk: moderate)  08/27/08 Comment


Cell Genesys, Inc. (CEGE) Halts Cancer Treatment Trial to Ensure Patient Safety
Logo1
38%

Cell Genesys, Inc. (Nasdaq: CEGE) focuses on the development and commercialization of biological therapies to treat multiple types of cancer. The company’s lead product platform, GVAX immunotherapy, holds the potential to treat various types of cancer, including prostate cancer, leukemia, pancreatic cancer and lung cancer. Cell Genesys today announced it has terminated VITAL-2, the second of two phase III clinical trials of GVAX.

<>The trial was set to compare GVAX immunotherapy in combination with Taxotere to Taxotere combined with prednisone in patients with advanced-stage prostate c...
By  StraightStocks   (-6.57%  risk: moderate)  08/27/08 Comment


Pre-Open Movers 8/27: SI International (SINT) Up on Buyout; Solarfun (SOLF) Falls After Results
<>StreetInsider.com Pre-Open Movers:

Cell Genesys, Inc. (Nasdaq: CEGE) 75% LOWER; terminated VITAL-2, the second of two Phase 3 clinical trials of GVAX immunotherapy for prostate cancer, which compares GVAX immunotherapy in combination with Taxotere(R) (docetaxel) to Taxotere plus prednisone in patients with advanced-stage prostate cancer. The Company ended the trial as recommended by its Independent Data Monitoring Committee (IDMC) which, in a routine safety review meeting held this week, observed an imbalance in deaths between the two treatment arms of the study.

NexMed, Inc. (Nasdaq: NEXM)...
By  Street Insider   (+9.67%  risk: moderate)  08/27/08 Comment


Option Update: Dendreon and Savient Pharma volatility elevated

Filed under: Options

Dendreon (NASDAQ: DNDN) expects the Independent Data Monitoring Committee (IDMC) to review in October 2008 the interim analysis of overall survival relating to the Company's Phase 3 IMPACT (Immunotherapy for Prostate AdenoCarcinoma Treatment). DNDN November call option implied volatility is at 164, puts are at 195; above its 26-week average of 129 according to Track Data, suggesting larger price fluctuations.

<>Savient Pharma (NASDAQ: SVNT) closed at $21.95 Thursday. SVNT's Puricase (treatment for refractory gout) BLA (biologics license application) filing is expected this ...
By  Paul Foster   (+0.00%)  08/22/08 Comment


Although Federal Reserve Policymakers Are Set to Meet, They Have Little Room to Maneuver
Logo1
38%

By William Patalon III Executive Editor Money Morning/The Money Map Report

U.S. Federal Reserve Chairman Ben S. Bernanke and his fellow central bank policymakers will be back in the spotlight this week as the group convenes for its monthly monetary-policy meeting.But there won’t be much to report.Although the Federal Reserve’s policymaking Federal Open Market Committee (FOMC) meets Wednesday, the group doesn’t have much room to maneuver: If the Fed cuts rates to stimulate growth, already troublesome inflation could escalate out of control. But if the FOMC raises rates to reign in<><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>< /><><><>< /><><>< /><>< /><>< />< />...
By  StraightStocks   (-6.57%  risk: moderate)  08/03/08 Comment



ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +34.25% 381
2 Gerald Greene 18.14 +72.34% 210
3 stockmarketfunding.com 17.66 +25.65% 55
4 akiralegrand 13.47 +14.32% 61
5 anup2104 12.13 +76.91% 39


POPULAR STOCKS
Symbol Company Name Sentiment
MO Altria Group Inc
F Ford Motor Company
BA The Boeing Company
KO The CocaCola Company
JNJ Johnson & Johnson
INTC Intel Corp

TODAY'S HEADLINES

TODAY'S TOP PICKS

 

StreetInsider.com on IDMC

Visit streetinsider.com


Discussion Wall + Add  

Be the first to start a discussion and earn 2 points.



More Resources

Graphic_arrow1 About INDYMAC BANCORP INC - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch